Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2022-09-06 00:00:00 ET · period of report 2022-09-01 · accession 0001104659-22-097874 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-09-06 | 2022-09-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +5,172 | 20.7K | +33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-09-01 | A | A | 5,172 | $0.00 | 20,716 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. |